オプションチェーンは、Inter & Coの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Inter & Coの市場センチメントを評価します。.

Inter & Co (NASDAQ:INTR) 株価情報, オプションチェーン

Inter & Co

Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop & Commerce Plus. It generates maximum revenue from the Banking & Spending.

Inter & Co Inc

Interlay - United States Dollar

INTRA ENERGY CORP LTD by INTRA ENERGY CORPORATION LTD

INTRED SPA by INTRED SPA

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies Inc

Intralot SA

Intralot SA ADR

INTREPID CAPITAL CORP by Intrepid Capital Corp.

Intrepid Capital Corp

Intrepid Metals Corp

INTREPID METALS CORP by INTREPID METALS CORP.

Intrepid Potash Inc

IntriEnergy Inc

Intrum AB

Intrum AB ADR

Intrusion Inc

Intrusion Precious Metals Corp

HC Wainwright &amp; Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) with a Buy and maintains $74 price target.

News

Price Target

Reiteration

Analyst Ratings

SWTX

HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $74 Price Target

On Thursday, Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.02</a>.
The automated insulin delivery technology maker reported sales of $597.5 million, up 17.2% year over year (17.1% in constant currency), beating the consensus of $582.81 million, exceeding the guidance range of 12% to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43865349/insulet-reports-full-year-2024-revenue-increase-of-22-and-fourth-quarter-2024-revenue-increase-of-" rel="noreferrer noopener">15% in constant currency</a>.
Total Omnipod revenue reached $585.7 million, an increase of 16.9%, or 16.8%, in constant currency. U.S. Omnipod revenue increased 12.4% to $443.7 million, and International Omnipod revenue rose to $142.0 million, an increase of 33.5%, or 33.1%, in constant currency.
Also Read: <a target="_blank" href="https://www.benzinga.com/etfs/sector-etfs/24/11/41853824/sp-500-breaks-6000-points-dow-soars-above-44000-small-caps-eye-strongest-week-in-4-years-tesla-hits-1-trillion-whats-driving-markets-friday" rel="noreferrer noopener">S&amp;P 500 Breaks 6,000 Points, Dow Soars Above 44,000, Small Caps Eye Strongest Week In 4 Years, Tesla Hits $1 Trillion: What's Driving Markets Friday?</a>
Drug Delivery revenue was $11.8 million, an increase of 34.1%. Gross margin expanded 120 basis points to 72.1%.
Operating income of $109.3 million, or 18.3% of revenue, fell 260 basis points, compared with operating income of $106.4 million, or 20.9% of revenue, in the prior year.
The company reported adjusted EBITDA of $151.2 million, or 25.3% of revenue, compared with $137.0 million, or 26.9% of revenue, in the prior year.
"We concluded an incredible year with a very strong fourth quarter, achieving significant milestones across the business and exceeding our growth and margin objectives," said Jim Hollingshead, Insulet President and Chief Executive Officer. "We continue to see robust demand and momentum for Omnipod 5, now available to both type 1 and type 2 patients in the U.S., and we continue to expand in international markets. We generated more than $2 billion in full-year revenue for the first time in Insulet's history, reached more customers, and continued to expand margins&#8230;"
Guidance: For 2025, Insulet expects revenue growth between 16% and 20%. It projects Omnipod sales to increase by 17%-21%. For Q1 2025, Insulet forecasts revenue growth between 22% and 25%, with U.S. Omnipod sales increasing by 21% % to 24%.
William Blair says Insulet's strong fourth-quarter performance confirms its growing momentum in the large, underpenetrated Type 1 and Type 2 diabetes markets.
Analyst Margaret Kaczor Andrew expects this trend to continue in 2025, driven by key growth catalysts that could accelerate adoption and revenue. With shares trading at 8.5 times the midpoint of 2025 sales guidance, William Blair maintains the stock as Outperform.
Price Action: PODD stock is down 2.76% at $280.33 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/02/43884348/nuburu-to-tap-private-equity-funds-for-strategic-acquisitions-in-defense-cybersecurity" target="_blank" rel="noreferrer noopener">Nuburu To Tap Private Equity Funds For Strategic Acquisitions In Defense, Cybersecurity</a></li>
</ul>
Photo via insulet

Analyst Color

Earnings

Guidance

Health Care

Movers

Trading Ideas

General

PODD

Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst

William Blair analyst Louie DiPalma downgrades General Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) from Outperform to Market Perform.

Downgrades

William Blair Downgrades General Dynamics to Market Perform

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan analyst Rajat Gupta downgraded the rating for TrueCar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUE#NASDAQ">TRUE</a>) from Overweight to Neutral. TrueCar shares closed at $2.67 on Thursday. <a href="https://www.benzinga.com/quote/true/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Madeline Brooks downgraded Akamai Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) from Buy to Neutral and lowered the price target from $125 to $100. Akamai shares closed at $98.03 on Thursday. <a href="https://www.benzinga.com/quote/akam/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Mark Fitzgibbon downgraded Amalgamated Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAL#NASDAQ">AMAL</a>) from Overweight to Neutral and lowered the price target from $42 to $38. Amalgamated Financial shares closed at $35.28 on Wednesday. <a href="https://www.benzinga.com/quote/amal/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel analyst Benjamin Nolan downgraded Cheniere Energy Partners, L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>) from Hold to Sell and raised the price target from $50 to $51. Cheniere Energy Partners shares closed at $63.14 on Thursday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Louie DiPalma downgraded the rating for Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) from Outperform to Market Perform. Booz Allen Hamilton shares closed at $113.62 on Thursday. <a href="https://www.benzinga.com/quote/BAH/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying BAH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="621" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21132625/image-179-1024x621.png" alt="" class="wp-image-793643" style="width:536px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21132625/image-179-1024x621.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21132625/image-179-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21132625/image-179-768x465.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21132625/image-179.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43864993/top-3-health-care-stocks-you-may-want-to-dump-in-february">Top 3 Health Care Stocks You May Want To Dump In February</a></li>
</ul>

AKAM

AMAL

TRUE

This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

HC Wainwright &amp; Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) with a Buy and maintains $21 price target.

ORIC

HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $21 Price Target

BofA Securities analyst Christopher Nardone reiterated a <a href="https://www.benzinga.com/quote/CROX/analyst-ratings">Buy rating</a> on the shares of footwear company Crocs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) with a price forecast of $153.
The analyst still believes management can meet its goal of modestly growing Crocs N.A. sales in 2025. Key factors include management's positive outlook on a strong wholesale order book for the next six months, along with the analyst&#8217;s optimistic view of upcoming product innovations, which have already received favorable feedback from wholesale partners.
These innovations include the InMotion clog (currently available at a $60 price point), global and product expansions of popular sandal styles like the Getaway, Miami, and Brooklyn, a greater focus on slippers (primarily in the second half of the year), and continued growth in Jibbitz and collaborations (with a full pipeline for this year).
For N.A. sales growth this year, the analyst anticipates a decline in first-quarter across both channels, followed by a rebound in second-quarter. 
First-quarter will face challenges from the leap year, Easter shifting to second-quarter, and a tougher wholesale comparison, with brick-and-mortar stores showing strong double-digit growth in first-quarter 2024, said the analyst.
International sales will remain the primary driver of overall brand growth for Crocs in 2025 and beyond, the analyst noted.
Also Read: <a href="https://www.benzinga.com/25/02/43880110/james-bond-franchise-shifts-hands-to-amazon-mgm-studios">James Bond&#8217;s New Era: Amazon MGM Studios Takes Creative Reins of Franchise</a>
<h2 class="wp-block-heading">Crocs&#8217; Growth Markets </h2>
According to the analyst, the biggest growth markets for Crocs this year, in terms of dollar value, are expected to be China, India, and Western Europe, including the UK, Germany, and France.
In 2024, India posed a challenge for the company due to regulatory hurdles that hindered supply from meeting demand. However, as 2025 progresses, the company anticipates an improvement in the supply situation. 
With four factories in India, up from three last year, Crocs plans to scale up production and increase output by the end of the year. This expansion will enable quicker distribution of sandals in India, a key move given the strong demand for sandals in the market.
Heydude is still in the early stages of recovery. <a href="https://www.benzinga.com/25/02/43691979/crocs-smashes-q4-earnings-expectations-amid-strong-china-growth-stock-jumps">Fourth-quarter progress</a> was promising, with better-than-expected digital performance and a return to positive DTC growth, the analyst said.
The analyst expects gross margins in 2025 to be similar to last year. But there may be a slight decline, according to official guidance.
Management plans to increase marketing spending to 10% of sales in 2025, up from 9% in 2024. This includes more investment in both brands, with Heydude focusing on brand awareness. 
The analyst is encouraged by the recent partnerships, including Sydney Sweeney, Jelly Roll, and Travis Hunter. Crocs will also boost influencer spending and maintain focus on Tier-1 markets.
HeyDude&#8217;s continued progress will drive multiple growth, the analyst added. Also, the company&#8217;s cash flow potential is undervalued.
Price Action: Crocs shares are trading higher by 0.25% at $109.15 at the last check Friday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43881721/coca-cola-warns-shortage-of-diverse-talent-could-harm-future-success">Coca-Cola Warns Shortage Of Diverse Talent Could Harm Business</a></li>
</ul>
Image: Shutterstock

CROX

Crocs Poised For Expansion, Analyst Counts China, India, Western Europe Among Biggest Growth Markets

At $2,930 on February 21, gold prices have been up 6.6% over the past 30 days and up 45% over the past year. Gold prices have crested the benchmark $3,000 per-ounce level, reaching $3,100 in mid-February.
That performance outpaces stocks, bonds, and most global currencies as volatility has taken hold of financial markets.
And that&#8217;s just the beginning. Wall Street analysts are forecasting even gold will keep rising this year.
Here are the three best ways to play that rise in gold prices.
A case in point &#8211; Goldman Sachs recently called gold prices to rise for the remainder of the year, between $3,100 and $3,300, as central bank demand and political instability push golf prices up by 10%.
&#8220;Policy uncertainty — including tariff fears — stays high; higher speculative positioning for longer could push gold prices as high as $3,300 an ounce by year-end,&#8221; noted Goldman strategist Lina Thomas in a recent research outlook.
Other analysts are in general agreement.
&#8220;A more forceful rally relative to our previous expectation is likely to be driven by deep-rooted bullish sentiment, with gold seen as a safe-haven asset amid a highly uncertain and volatile macro environment,&#8221; UBS said in a new research note.
Commodity sector insiders are even more bullish, with a $4,000 gold price in the cards.
"The current surge in gold prices and demand underscores the profound uncertainty gripping individual investors and global markets,&#8221; said Paul Williams, managing director at Solomon Global, a certified gold and silver bars and coin supplier. "This doesn't look like a short-lived rally —it's a response to entrenched geopolitical tensions, economic fragility, and shifting global power dynamics."
As volatility escalates, gold remains the ultimate hedge, offering stability in an increasingly unpredictable world. "Considering these factors, the $3,000 milestone looks feasible in the next few weeks, and if gold was to make the same gains as it has over the last 12 months, we're looking at $4,250 this time next year," Williams says.
Other gold watchers are pumping the breaks, noting that major global currency movements could tamp commodity prices down in 2025.&nbsp;
"Gold prices will remain elevated throughout 2025 against the backdrop of increased Central Banks purchases, mounting concerns about disruptive US tariffs and demand from newly introduced gold ETFs," said Peter Smith, senior international equity strategist at Federated Hermes, which regularly tracks gold prices. "Central banks are increasingly moving away from Treasuries as investments for their currency reserves, with China in particular, sitting on a $1 trillion trade surplus in 2024, is aggressively buying gold."
However, gold could weaken if the interest rate differential stays wide between the US and the rest of the world. "This could lead to the dollar remaining strong, which should put downward pressure on gold," Smith says. "This is not our base case, but with inflation sticky in the US, the Federal Reserve has signaled it is willing to keep rates higher for longer."
<h2 class="wp-block-heading">Three Gold Plays to Make in 2025</h2>
So, while the trend remains positive for gold and other commodities (silver, for instance, is up 40% so far in 2025), here&#8217;s what sector experts say is the smart play for investors looking to add a yellow hedge to their portfolios.
Gold mining stocks. Stocks of companies that mine gold, such as Newmont (USA), Barrick Gold (Canada), and Freeport McMoRan (USA), offer the opportunity to profit when the metal's price rises, says Julia Khandoshko, CEO of broker Mind Money, a European investment technology and financial engineering hub.
"Investors should note that gold mining stocks can also be risky, so factor that reality into portfolio selection and discuss any trades with a trusted financial advisor," Khandoshko says. "Nevertheless, gold mining stocks can offer better returns than direct investments, especially if the chosen company manages its resources effectively and successfully copes with external challenges."
Gold ETFs. For new investors, spot gold ETFs like SPDR Gold Shares (GLD) can be the easiest and most efficient way to gain exposure to gold, with the larger sector ETFs making the most sense right out of the gate.
Gold ETFs are one of the best options for investing in gold efficiently without the hassle of storing physical bars. "They track the price of gold and are easy to buy and sell, just like a stock," says Chris Heerlein, CEO of REAP Financial, an investment advisory firm based in Austin, Texas.&nbsp;
GLD has some other features gold fund investors might appreciate.
"In addition to being highly liquid, SPDR Gold Shares has always been my favorite gold ETF for two reasons," said Michael Martin, vice president of market strategy at TradingBlock, a Chicago-based market technology trading company. "First, it holds physical gold as opposed to gold futures, so it doesn't suffer decay in value over time. Second, it has the highest assets under management, at $78.1 billion in net assets." The fund is trading at $270 as of February 21.
Physical gold. If you feel ambitious and want direct control over your gold investment, consider investing in physical gold.
"Buying physical gold is a good move because it's the safest and most reliable, as it eliminates counterparty risk," says Alex Ebkarian, COO and co-founder at California-based Allegiance Gold. "It fits the needs of those looking to preserve wealth, diversify their portfolio, and most importantly want and desire to maintain control of the asset and eliminate counterparty risk and addresses declining trust in paper gold."
Buying physical gold requires having "a mid-to-long term outlook on return on investment, as well as preferring ownership of a physical asset versus exposure to the gold stock or fund sector," Ebkarian added.
<a href="https://www.benzinga.com/premium/ideas/benzinga-edge/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0224&amp;utm_campaign=wallstreetadvantage">Cut Through the Market Chaos—Get One Clear Trade Every Morning</a>
Wild swings. Mixed signals. Uncertain trends. Every morning, we deliver one crystal-clear ‘Chart of the Day'—a high-potential setup or a crucial trade to avoid. Get ahead of the market before the next move happens. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0224&amp;utm_campaign=wallstreetadvantage">Get My Chart Now</a>
Image via Shutterstock

Opinion

3 Best Gold Plays for a Volatile 2025

William Blair analyst Louie DiPalma downgrades Parsons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) from Outperform to Market Perform.

William Blair Downgrades Parsons to Market Perform

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Hold to Hold.

ITCI

Needham Reiterates Hold on Intra-Cellular Therapiesto Hold

JP Morgan&nbsp;analyst Rajat Gupta&nbsp;downgraded TrueCar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUE#NASDAQ">TRUE</a>)<a target="_blank" href="https://www.benzinga.com/quote/true/analyst-ratings" rel="noreferrer noopener"> from Overweight to Neutral</a>.
This week, the company reported fourth-quarter EPS loss of 7 cents per share, falling short of the analyst consensus estimate of loss of 6 cents&nbsp;and revenue&nbsp;of $46.21 million,&nbsp;missed the consensus&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43796921/truecar-releases-fourth-quarter-2024-financial-results-and-stockholder-letter" rel="noreferrer noopener">estimate of $47.29 million</a>.
The analyst cites the weakening tailwinds from inventory and limited visibility on a sustained turnaround in revenue and profits as reasons for the downgrade.&nbsp;
The analyst writes that it was a disappointing quarter for the company with an uncertain path to recovery in growth and profitability, especially as the boost from rising new vehicle inventories begins to fade.&nbsp;
While upcoming products like TCMS, OEM advertising, and data monetization, along with TC+ integration into DMS platforms, offer potential, TRUE must demonstrate clear results from its initiatives and investments in sales and marketing, adds the analyst.
The analyst says that&nbsp;the possibility of a merger or partnership with industry peers cannot be ruled out.&nbsp;
Gupta revised the FY25 EBITDA estimate from the previous +$15 million to breakeven due to weaker dealer revenue. The analyst also lowered the FY26 estimate from +$35 million to +$25 million. 
Due to these significantly reduced projections, the analyst also withdrew his price forecast on the stock.
Price Action: TRUE shares are down 5.21% at $2.531 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43885302" target="_blank" rel="noreferrer noopener">Apple Expands Apple TV+ to Android, Eyes Subscription Growth and Ecosystem Expansion, Analyst Says</a></li>
</ul>
Photo by Ground Picture on Shutterstock.

Equities

TrueCar's Outlook Is Cloudy, Analyst Downgrades Stock Seeking More Visibility

HC Wainwright &amp; Co. analyst Mike Colonnese reiterates Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Buy and maintains $350 price target.

COIN

HC Wainwright & Co. Reiterates Buy on Coinbase Global, Maintains $350 Price Target

William Blair analyst Louie DiPalma downgrades CACI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) from Outperform to Market Perform.

CACI

William Blair Downgrades CACI International to Market Perform

<a href="https://www.benzinga.com/25/02/43803016/is-jack-dorsey-the-mysterious-satoshi-nakamoto-vanecks-matthew-sigel-points-key-evidence-linking-twitter-founder-to">VanEck's Head of Digital Assets Research</a>, Matthew Sigel, has laid out a vision for how the U.S. Treasury could use Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to strengthen its balance sheet.
What Happened: In a post on <a href="https://x.com/matthew_sigel/status/1892654369025245281">X</a> on Friday, Sigel highlighted VanEck's estimates that if Bitcoin appreciates at 25% annually—rising from $100,000 today to $21 million per BTC by 2049—the reserve could offset 18% of the projected U.S. debt.
This assumes debt grows at 5% annually, reaching $116 trillion by 2049 (up from $36 trillion in 2025).
While this theory is highly optimistic, it underscores Bitcoin's potential as a sovereign reserve asset and a hedge against inflationary debt expansion.
The BITCOIN Act introduced by Wyoming Senator Cynthia Lummis proposes the U.S. accumulate 1 million BTC over five years and hold it for at least 20 years as a strategic Bitcoin reserve.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43852658/bitcoin-ethereum-face-downside-risk-as-institutional-demand-fades-jpmorgan-says">Bitcoin, Ethereum Face Downside Risk As Institutional Demand Fades, JPMorgan Says</a>
Why It Matters: Polymarket now <a href="https://polymarket.com/event/us-national-bitcoin-reserve-in-2025?tid=1740147906234">prices</a> in a 44% chance of a U.S. National Bitcoin Reserve in 2025, up from 39% earlier this month. 
Kalshi <a href="https://kalshi.com/markets/kxbtcreserve/bitcoin-reserve">data</a> sees a 59% probability that Trump would establish a Bitcoin Reserve if elected, up from 53.8% on Feb. 12.
Arkansas is set to become the first state to establish a Bitcoin reserve, with amendments expected by March 5. Meanwhile, Texas is preparing to debate the proposal in its Senate.
What's Next: Momentum is building for Bitcoin as a national strategic asset, with state-level initiatives paving the way for potential federal adoption. 
While still speculative, institutional support and policy discussions could shape Bitcoin's future as a financial pillar in the U.S. economy.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43861244/xrp-to-be-part-of-the-crypto-reserve-after-donald-trumps-social-media-post-not-so-fast-pol">XRP To Be Part Of The Crypto Reserve After Donald Trump&#8217;s Social Media Post? Not So Fast, Polymarket Traders Say</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Reserve With 1 Million BTC Could Offset $21 Trillion National Debt By 2049, Expert Says

William Blair analyst Louie DiPalma downgrades Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) from Outperform to Market Perform.

William Blair Downgrades Booz Allen Hamilton to Market Perform

Needham analyst Charles Shi reiterates Altair Engineering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTR#NASDAQ">ALTR</a>) from Hold to Hold.

ALTR

Needham Reiterates Hold on Altair Engineeringto Hold

Stephens &amp; Co. analyst Jim Salera maintains Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Equal-Weight and lowers the price target from $186 to $180.

TXRH

Stephens & Co. Maintains Equal-Weight on Texas Roadhouse, Lowers Price Target to $180

WIIM

Bluelinx Holdings shares are trading lower. Multiple firms lowered their respective price targets on the stock.

AMN Healthcare Services shares are trading higher after the company reported better-than-expected Q4 financial results.

Amalgamated Financial shares are trading lower after Piper Sandler downgraded the stock from Overweight to Neutral and lowered its price target from $42 to $38.

RBC Capital analyst Steven Shemesh maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Outperform and lowers the price target from $109 to $107.

RBC Capital Maintains Outperform on Walmart, Lowers Price Target to $107

Press Releases

Inter&Co Inc. Reports Record Profit

S&P reviews Banco Inter's outlook to Stable and reaffirms its "brAA+" rating

Inter&Co doubles down on SMEs through acquisition of Granito

Moody's assigns debut AA+.br ratings to Inter, recognizing strong financial position

Inter&Co Inc. Reports Record Profit in Q2, Advances 60/30/30 Plan

Inter&Co Inc. Reports Another Record Net Income of R$260M, And Remains On Track On Its Long-Term Plan

Inter&Co Inc. Reports Highest Ever Net Income of R$973M in 2024

INTR

Grupo Aval Acciones y Valores S.A. ADR (Each representing 20 preferred shares)

Grupo Aval Acciones

Credicorp

Banco BBVA Argentina

Banco De Chile

Banco Macro S.A. ADR (representing Ten Class B Common Shares)

Banco Macro

Banco Santander Chile

BanColombia

Comerica

Grupo Financiero Galicia S.A. - American Depositary Shares, Class B Shares underlying

Grupo Financiero Galicia

Intercorp Financial Services Inc. Common Shares

Intercorp Financial Servs

Shinhan Financial Group Co Ltd American Depositary Shares

Shinhan Finl Gr

Grupo Supervielle S.A. American Depositary Shares each Representing five Class B shares

Grupo Supervielle

Woori Financial Group Inc. American Depositary Shares (each representing three (3) shares of Common Stock)

Comments

Inter & Co

Inter & Co (INTR) オプション

Inter & Co (NASDAQ:INTR) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル